Saturday, 3 October 2026European Markets

GJENSIDIGE FORSIKR And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Loading stream...

(vianews) - gjensidige forsikr (gjf.ol), savencia (save.pa), airbus (air.pa) are the highest sales growth and return on equity stocks on this list.

here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. may these stocks be a good medium-term investment option?

1. gjensidige forsikr (gjf.ol)

83.1% sales growth and 21.65% return on equity

gjensidige forsikring asa provides general insurance and pension products in norway, sweden, denmark, latvia, lithuania, and estonia. the company operates through six segments: general insurance private, general insurance commercial, general insurance denmark, general insurance sweden, general insurance baltics, and pension. it offers motor, accident and health, travel, leisure craft, valuables, liability, commercial, marine/transport, agriculture, natural perils, life, and pet insurance products. the company also provides defined contribution occupational pension schemes for businesses, which include disability pension, spouse/cohabitant pension, and child's pension products. it distributes its products through various distribution channels comprising office channel, call center, internet, partners, and brokers to private and commercial customers. the company was founded in 1816 and is headquartered in oslo, norway.

earnings per share

as for profitability, gjensidige forsikr has a trailing twelve months eps of kr9.4.

pe ratio

gjensidige forsikr has a trailing twelve months price to earnings ratio of 19.38. meaning, the purchaser of the share is investing kr19.38 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.65%.

sales growth

gjensidige forsikr's sales growth for the next quarter is 83.1%.

yearly top and bottom value

gjensidige forsikr's stock is valued at kr182.20 at 12:20 est, way below its 52-week high of kr212.20 and way above its 52-week low of kr164.50.

volume

today's last reported volume for gjensidige forsikr is 19164 which is 94.73% below its average volume of 364065.

more news about gjensidige forsikr.

2. savencia (save.pa)

16.8% sales growth and 4.84% return on equity

savencia sa engages in production, distribution, and marketing of dairy and cheese products in france, rest of europe, and internationally. the company provides butters and creams for the retail market and catering professionals; and dairy ingredients for the food, nutrition, and healthcare industries. it offers its products under the capricedesdiex, elle & vire, smoret, saint agur, tatare, saint albray, le rustique, fol epi, richesmonts, chavroux, coeur of lion, roquefort papillon, geramont, milkana, bresso, brunch, etc. the company was formerly known as bongrain sa and changed its name to savencia sa in april 2015. savencia sa was founded in 1956 and is headquartered in viroflay, france. savencia sa operates as a subsidiary of savencia holding sca.

earnings per share

as for profitability, savencia has a trailing twelve months eps of €6.39.

pe ratio

savencia has a trailing twelve months price to earnings ratio of 9.83. meaning, the purchaser of the share is investing €9.83 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.84%.

yearly top and bottom value

savencia's stock is valued at €62.80 at 12:20 est, below its 52-week high of €66.00 and way above its 52-week low of €50.70.

sales growth

savencia's sales growth is 16.8% for the present quarter and 16.8% for the next.

volume

today's last reported volume for savencia is 33 which is 96.93% below its average volume of 1077.

more news about savencia.

3. airbus (air.pa)

14.7% sales growth and 53.48% return on equity

airbus se engages in the design, manufacture, and delivery of aerospace products, services, and solutions worldwide. it operates through three segments: airbus, airbus helicopters, and airbus defence and space. the airbus segment develops, manufactures, markets, and sells commercial jet passenger aircraft; freighter aircraft; and regional turboprop aircraft and aircraft components, as well as provides aircraft conversion and related services. the airbus helicopters segment engages in the development, manufacture, marketing, and sale of civil and military helicopters; and provision of helicopter related services. the airbus defence and space segment designs, develops, delivers, and supports military aircraft, such as combat, mission, transport, tanker aircraft, and their associated services; a range of civil and defence space systems for telecommunications, earth observations, navigation, science, and orbital systems; and unmanned aerial systems. this segment also offers missile and space launcher systems, as well as services around data processing from platforms, secure communication, and cyber security. the company was formerly known as airbus group se and changed its name to airbus se in april 2017. airbus se was incorporated in 1998 and is based in leiden, the netherlands.

earnings per share

as for profitability, airbus has a trailing twelve months eps of €5.18.

pe ratio

airbus has a trailing twelve months price to earnings ratio of 23.39. meaning, the purchaser of the share is investing €23.39 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 53.48%.

yearly top and bottom value

airbus's stock is valued at €121.16 at 12:20 est, under its 52-week high of €126.04 and way above its 52-week low of €86.52.

more news about airbus.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com